This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gunawan, B. Articles by Füzesi, L. Search for Related Content PubMed PubMed Citation Articles by Gunawan, B. Articles by Füzesi, L.

Cytogenetic and Morphologic Typing of 58 Papillary Renal Cell Carcinomas

Evidence for a Cytogenetic Evolution of Type 2 from Type 1 Tumors

Institute of Pathology [B. G., T. F., L. F.] and Department of Urology [R-H. R.], University of Göttingen, 37075 Göttingen; Department of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, 14195 Berlin [A. v. H.]; Division of Molecular Genome Analysis, German Cancer Research Center, 69120 Heidelberg [W. H.]; and Department of Urology, University of Aachen, 52057 Aachen [G. J.], Germany

We evaluated clinical characteristics, patient outcome (mean follow-up, 47 months), and cytogenetic abnormalities in the largest as yet reported cytogenetic series of 47 primary and 11 secondary papillary renal cell carcinomas for differences between the recently proposed type 1 and type 2 subtypes. Secondary tumors were more often of type 2 morphology (P = 0.02), whereas primary type 2 tumors were associated with higher clinical stage (P = 0.001) and worse patient outcome (P = 0.02). Although both subtypes had at least one of the primary chromosomal gains at 17q, 7, and 16q, type 2 tumors had moderately lower frequencies of primary gains at 17p (61 versus 94%; P = 0.007) and 17q (72 versus 97%; P = 0.02). On the other hand, type 2 tumors overall had more chromosomal alterations than type 1 tumors (P = 0.01), particularly gains of 1q (28 versus 3%; P = 0.02) and losses of 8p (33 versus 0%; P = 0.001), 11 (28 versus 3%; P = 0.02), and 18 (44 versus 9%; P = 0.01). Hierarchical clustering suggested cytogenetic patterns common but not restricted to type 2 morphology, one characterized by multiple additional gains, and another predominantly showing additional losses. These findings provide genetic evidence that type 1 and type 2 tumors arise from common cytogenetic pathways and that type 2 tumors evolve from type 1 tumors. Independently of type, losses of 9p were statistically correlated with advanced disease (P = 0.0008) and may serve as a potential adverse prognostic marker in papillary renal cell carcinomas.

This article has been cited by other articles:

				K. A. Furge, J. Chen, J. Koeman, P. Swiatek, K. Dykema, K. Lucin, R. Kahnoski, X. J. Yang, and B. T. Teh Detection of DNA Copy Number Changes and Oncogenic Signaling Abnormalities from Gene Expression Data Reveals MYC Activation in High-Grade Papillary Renal Cell Carcinoma Cancer Res., April 1, 2007; 67(7): 3171 - 3176. [Abstract] [Full Text] [PDF]

				H. T. Cohen and F. J. McGovern Renal-Cell Carcinoma N. Engl. J. Med., December 8, 2005; 353(23): 2477 - 2490. [Full Text] [PDF]

				X. J. Yang, M.-H. Tan, H. L. Kim, J. A. Ditlev, M. W. Betten, C. E. Png, E. J. Kort, K. Futami, K. A. Furge, M. Takahashi, et al. A Molecular Classification of Papillary Renal Cell Carcinoma Cancer Res., July 1, 2005; 65(13): 5628 - 5637. [Abstract] [Full Text] [PDF]

				H. Sultmann, A. v. Heydebreck, W. Huber, R. Kuner, A. Buness, M. Vogt, B. Gunawan, M. Vingron, L. Fuzesi, and A. Poustka Gene Expression in Kidney Cancer Is Associated with Cytogenetic Abnormalities, Metastasis Formation, and Patient Survival Clin. Cancer Res., January 15, 2005; 11(2): 646 - 655. [Abstract] [Full Text] [PDF]